Compare NBIX & PNFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | PNFP |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 14.6B |
| IPO Year | 1996 | 2025 |
| Metric | NBIX | PNFP |
|---|---|---|
| Price | $135.92 | $92.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 29 | 22 |
| Target Price | ★ $206.81 | $118.86 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 11-02-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 2.14% |
| EPS Growth | ★ 41.95 | 35.40 |
| EPS | ★ 3.30 | 2.96 |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $36.39 | $145.52 |
| Revenue Next Year | $16.93 | $8.49 |
| P/E Ratio | $40.95 | ★ $31.60 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $81.08 |
| 52 Week High | $186.12 | $110.33 |
| Indicator | NBIX | PNFP |
|---|---|---|
| Relative Strength Index (RSI) | 32.66 | 37.96 |
| Support Level | $125.18 | $81.76 |
| Resistance Level | $138.74 | $99.77 |
| Average True Range (ATR) | 3.60 | 2.07 |
| MACD | -0.05 | 0.09 |
| Stochastic Oscillator | 22.43 | 16.85 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.